Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933528 · ClinicalTrials.gov registry record · Phase 2
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
A Phase 2 study of Psoriasis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02933528 is a Phase 2 study of Psoriasis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 24 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02933528, a Phase 2 study of Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
Conditions Studied
Interventions
- DRUG DSXS Topical product
Study Locations (1)
New York
- Taro Pharmaceuticals USA, Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933528
The ClinicalTrials.gov registry entry for NCT02933528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DSXS Topical product is the first listed.
NCT02933528 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02933528 about?
NCT02933528 is a clinical study titled "Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS". An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
What is the current status of trial NCT02933528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-07-11. Estimated completion is 2017-11-27.
What conditions does trial NCT02933528 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02933528?
The interventions under investigation include: DSXS Topical product (DRUG).
Who is sponsoring clinical trial NCT02933528?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933528 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.